Status: Recruiting
PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer
The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.
Participants needed: 53
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: Samsung Medical CenterUpdated: May 28, 2026Locations: 1
Eligibility criteria
Not listed